title: Evaluation of Lp-PLA2 mass, vitronectin and PAI-1 activity levels in patients with preeclampsia.
abstract: OBJECTIVE
  The aim of the current study is to determine, correlate and compare the plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), vitronectin (Vn), Plasminogen activator inhibitor-1 (PAI-1) activity and tissue plasminogen activator (t-PA) levels in early-onset preeclampsia, late-onset preeclampsia and in control pregnant women.
  
  
  METHODS
  A total of 79 individuals, 30 early-onsets, and 22 late-onset preeclamptic and 27 control pregnant women were included into the scope of this study. Enzyme-linked immunosorbent assay procedure was used to determine the serum Lp-PLA2 and plasma Vn, t-PA antigen and PAI-1 activity levels. Serum C-reactive protein (CRP) levels were measured immunoturbidimetrically in routine clinical chemistry analyser.
  
  
  RESULTS
  In patients with preeclampsia, Lp-PLA2, PAI-1, t-PA, CRP and blood pressures levels were increased (p = 0.000) and correlated with each other. Vn levels were decreased (p = 0.016) but not correlated with other parameters in preeclamptic patients.
  
  
  CONCLUSIONS
  We are of the opinion that increased Lp-PLA2 levels may partially contribute to endothelial dysfunction by the progression of inflammation. In addition, increased complex formation with Vn is likely to bring about the increase of PAI-1 activity in patients with preeclampsia. Moreover, increased t-PA and decreased Vn levels may also be the consequences of compensatory mechanisms against disease progression.
authors.affiliation: Department of Biochemistry, Cerrahpasa Medical School, University of Istanbul, Istanbul, Turkey.
authors.forename: Özlem
authors.initials: Ö
authors.lastname: Balcı Ekmekçi
authors.forename: Hakan
authors.initials: H
authors.lastname: Ekmekçi
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Güngör
authors.forename: Abdullah
authors.initials: A
authors.lastname: Tüten
authors.forename: M Sait
authors.initials: MS
authors.lastname: Toprak
authors.forename: Meltem
authors.initials: M
authors.lastname: Korkmaz
authors.forename: Mahmut
authors.initials: M
authors.lastname: Öncül
authors.forename: Oktay
authors.initials: O
authors.lastname: Çalışkan
authors.forename: Mine
authors.initials: M
authors.lastname: Kucur
authors.forename: Orkide
authors.initials: O
authors.lastname: Donma
authors.forename: Rıza
authors.initials: R
authors.lastname: Madazlı
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Sönmez
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood*; D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D011225:Pre-Eclampsia / Q000097:blood*; D011247:Pregnancy; D010959:Tissue Plasminogen Activator / Q000097:blood; D019096:Vitronectin / Q000097:blood*; D055815:Young Adult
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D019096:Vitronectin; D002097:C-Reactive Protein; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D010959:Tissue Plasminogen Activator